Clinical Trial

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before surgery. It is intended to further explore the efficacy and safety of the new adjuvant treatment for TPBC patients with step-down therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-23.
Status change: Not Yet Recruiting → Recruiting 2024-12-12
Trial Details
NCT Number NCT06276868
Lead Sponsor Henan Cancer Hospital
Conditions Breast Cancer, HER2-positive Breast Cancer
Enrollment 71 participants
Start Date 2024-01-20
Primary Completion 2025-07-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-17